ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
2,289 announcements with these filters
H1 FY27 showed strong growth: disbursements over ₹35,000 Cr (+37%) and loan book up 29% to ₹1.86 lakh Cr. Management reaffirmed ~2% spread and ~3% NIM despite funding-cost pressure.
Q2 FY27 revenue ₹1,746 Cr, +89.9% YoY; EBITDA margin 17.6%, reported PAT ₹185.5 Cr. Management says H2 margins will be lower than Q2; EBITDA guidance held at 14–15%.
Q2 FY27 revenue rose 31% YoY to ₹309.6 Cr on 13% volume growth. EBITDA recovered to ₹11.5 Cr (3.7% margin) from ₹3 Cr in Q1, but management says margins are still below target. Kissan remains loss-making.
Q2FY27 revenue ₹238.0 Cr (+48% YoY), EBITDA ₹20.3 Cr (8.5% margin), PAT ₹9.5 Cr (+54%). Volume-led recovery, utilisation 70%; FY27 EBITDA margin guided 11–12%.
Q2 top-line grew ~13% but volume only ~5%, as festive sweets shifted into Q3. YTD growth guidance raised to 17%+, while Q3 margins face pressure.
Consolidated revenue rose 40% to ₹299 Cr, but a ₹39 Cr loss persists after a ₹57 Cr treasury fair-value hit. H-acid price gains are expected to lag into Q3–Q4.
Consolidated revenue rose 32% to ₹6,042 Cr and PAT reached ₹184 Cr (+19%). FY27 8-10% growth guidance was retained, implying a steep H2 slowdown that management did not quantify.
Q2 consolidated revenue of ₹1,035 Cr (+32%) and PAT of ₹296 Cr rest on a one-time ₹194 Cr Panipat stake-sale gain. Underlying growth is modest.
Premium growth is strong, but Q2 profit fell year on year to ₹2,455.62 Cr as the claims ratio rose to 87.39%. Management deflected on catastrophe losses, combined-ratio targets and Ind AS impact.
Q2 revenue ~₹502 Cr (+32.7%) and PAT ₹98 Cr (+32.8%), volume-led. H1 operating cash flow only ₹124 Cr. Margin guidance is qualitative, implying FY26-level margins.
Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.
Q2 FY27 revenue ₹2,749 Cr (+25% YoY, flat QoQ) and PAT ₹131 Cr (+21%), but EBITDA margin slipped to 10.2% from 11.1%. Management maintained 20–25% FY27 growth; margin commentary remains hedged.
Record Q2 revenue of ₹1,091.5 Cr (+32%) and PAT +52%, with EBITDA margin up to 19.4% on mix. Wage and freight costs were absorbed, but working capital and net debt rose with capex.
Record ₹2,900 Cr disbursement, AUM up 22%, standalone PAT ₹110.8 Cr. Credit cost 2.6%. Management downplays drought exposure of 3.6% of book.
Q2 revenue rose 7.8% to ₹633.2 Cr, but EBITDA margin fell about 270bps to 21.3%. H1 growth was only 3.9%, yet management targets about 10% FY27 growth while refusing margin guidance and hedging on FY28-29.
Q2 FY27 revenue ₹280 Cr (+43%) and EBITDA ₹94 Cr (+88%) were flattered by a ₹53 Cr one-time DCV milestone. Management sounds confident, but pricing and timing answers stayed unquantified.
Consolidated Q2 revenue ₹7,615 Cr (+23%), EBITDA ₹1,191 Cr (+29%), margin 15.6% vs 14.9%. Growth is solid, but Apollo Health Co's FY27 margin outlook was trimmed and management avoided explicit hospital growth guidance.
H1 FY27 revenue ₹219 Cr (vs ₹77 Cr) is 84% Q2-loaded; PAT ₹5.8 Cr, EBITDA margin 14.2%. Management declined any guidance, deflecting to an annual view.
Q2FY27 total income ₹1,135 Cr (+13% YoY), EBITDA ₹127 Cr (+52%), EBITDA margin 11.2% (+287 bps), PAT ₹41 Cr. India and Africa both grew, aided by a weak prior-year US tariff base.
Like-for-like growth ~20% and ex-IGI EBITDA margin 21%, yet H1 operating cash was negative; H2 cash recovery is the test.
H1 FY27 sales ₹3,800 Cr, about 40% of the ₹10,000 Cr FY27 target, which management reaffirmed. Q2 EBITDA margin was 18% versus 13% for H1. No YoY growth was quantified.
Q2 FY27 revenue Rs 5,542 Cr (+16.6% YoY), PAT Rs 721 Cr (+10.2%), profit-from-operations margin 17.0%. H1 revenue Rs 10,506 Cr (+13.1%). Growth broad-based across channels.
H1 FY27 revenue ₹1,213 Cr (+17% YoY), EBITDA ₹335 Cr (28% margin), PAT ₹172 Cr (+19%). Q2 revenue ₹659 Cr (+23%). Strategy: integrated CRDMO, larger strategic pharma engagements, ₹621 Cr H1 capex.
H1FY27 revenue ₹36.12 Cr (+64.93%), EBITDA ₹5.74 Cr (15.89% margin), PAT ₹3.20 Cr (+223%). Pivot to four value-added verticals and 4,200 MT/month capacity.
Q2 FY27 revenue ₹633 Cr (+7.8% YoY), EBITDA margin 21.3%, PAT ₹81.9 Cr (-10% YoY). Focus on input-cost inflation, festive demand shifting into Q3, and Rajasthan steel bottle ramp-up.
H1 FY27 revenue ₹22.32 Cr (+65.2%), EBITDA ₹4.09 Cr (18.3% margin), PAT ₹2.80 Cr (+129.5%). Strategy: scale overseas and move to product-led revenue.
Q2FY27 revenue ₹115.7 Cr (+19.8% YoY), EBITDA ₹37.4 Cr (31.4% margin), PAT ₹26.2 Cr (+15.4%). H1FY27 revenue ₹219.0 Cr, PAT ₹46.2 Cr (+43.9%). Growth via acquisitions.
Q2 FY27 standalone revenue ₹275 Cr (+2%), EBITDA ₹37 Cr (+22%), PAT ₹27 Cr (+42%), EBITDA margin 13.3%. Diversification offset a weak agro season.
Q2 FY27 PAT ₹15.06 Cr (+148.5% YoY) on AUM ₹1,766 Cr. Book shifting to Mediclaim and Salary Saathi; GNPA 1.77%.
Q2 FY27: total income ₹16.79 Cr, PBT ₹8.72 Cr, net profit margin 38.42%. Disbursements grew 77.64% Q/Q. No explicit guidance given.